| Literature DB >> 26740500 |
Zhuoqiang Lu1, Xuemei Wu2, Xueqing Jin3, Feng Peng4, Jinxiu Lin4.
Abstract
OBJECTIVE: A meta-analysis of the association between haplotypical variants of the apolipoprotein E (APOE) gene (ɛ2/ɛ3/ɛ4) and obstructive sleep apnoea (OSA) risk and changes in lipid profile.Entities:
Keywords: Obstructive sleep apnoea; apolipoprotein E; meta-analysis; variant
Mesh:
Substances:
Year: 2016 PMID: 26740500 PMCID: PMC5536579 DOI: 10.1177/0300060515611539
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Flow diagram of search strategy and study selection for a meta-analysis evaluating the association between obstructive sleep apnoea (OSA) risk and the apolipoprotein gene (APOE) ɛ2/ɛ3/ɛ4 alleles.
Characteristics of studies included in a meta-analysis evaluating the association between obstructive sleep apnoea risk and the apolipoprotein gene (APOE) ɛ2/ɛ3/ɛ4 alleles.
|
| Age, years | Male sex, % | |||||||||||
| Author, year | Country | Design | Source | AHI cut off | Method | Cases | Controls | Cases | Controls | Cases | Controls | ||
| Uyrum, 2015[ | Turkey | Pro | Hosp | ≥5 | PSG | 42 | 31 | 54 | 44 | 59.5 | 38.8 | ||
| Tisko (mild), 2014[ | Slovakia | Retro | Hosp | >5–<15 | PSG | 126 | 128 | 49.5 | 47.8 | 70.6 | 53.1 | ||
| Tisko (moderate), 2014[ | Slovakia | Retro | Hosp | > 15–<30 | PSG | 66 | 128 | 51.6 | 47.8 | 68.2 | 53.1 | ||
| Tisko (severe), 2014[ | Slovakia | Retro | Hosp | ≥30 | PSG | 199 | 128 | 51.2 | 47.8 | 83.9 | 53.1 | ||
| Osorio (mild), 2014[ | USA | Pro | Pop | >5–15 | PSG | 52 | 25 | 67.8 | 65.3 | 41.2 | 32.0 | ||
| Osorio (moderate/ severe), 2014[ | USA | Pro | Pop | ≥15 | PSG | 19 | 25 | 70.1 | 65.3 | 42.1 | 32.0 | ||
| Nikodemova (mild), 2013[ | USA | Pro | Pop | >5–<15 | PSG | 399 | 1146 | 56.4 | 52.1 | 62.2 | 54.1 | ||
| Nikodemova (moderate/ severe), 2013[ | USA | Pro | Pop | ≥15 | PSG | 298 | 1146 | 56.6 | 52.1 | 71.5 | 54.1 | ||
| Cosentino, 2008[ | Italy | Retro | Pop | ≥15 | PSG | 123 | 121 | 58.6 | 57.9 | 66.7 | 64.5 | ||
| Sheng, 2008[ | China | Retro | Pop | ≥5 | PSG | 84 | 106 | 48.6 | 49.8 | 86.9 | 86.8 | ||
| Zheng, 2007[ | China | Retro | Hosp | ≥5 | PSG | 50 | 40 | 39 | 44.5 | 100 | 100 | ||
| Gozal, 2007[ | USA | Retro | Pop | >1 | PSG | 112 | 146 | 6.3 | 6.4 | 54.1 | 55.4 | ||
| Craig, 2006[ | UK | Retro | Hosp | Other | NPI-D | 217 | 185 | 78 | 78 | 40.0 | 33.0 | ||
| Larkin (white), 2006[ | USA | Pro | Pop | ≥15 | PSG | 218 | 796 | 40 | 38.7 | 48.2 | 45.7 | ||
| Larkin (black), 2006[ | USA | Pro | Pop | ≥15 | PSG | 197 | 796 | 37.1 | 38.7 | 42.8 | 45.7 | ||
| Gottlieb, 2004[ | USA | Pro | Pop | ≥15 | PSG | 337 | 1438 | 71 | 71 | 45.0 | 45.0 | ||
| Kadotani, 2001[ | USA | Pro | Pop | ≥15 | PSG | 66 | 725 | 49 | 49 | 58.3 | 58.3 | ||
| Foley, 2001[ | USA | Pro | Pop | ≥15 | PSG | 302 | 416 | NA | NA | 100 | 100 | ||
| Saarelainen, 1998[ | Finland | Retro | Pop | ≥5 | PSG | 291 | 728 | 53.3 | 53.7 | 90.7 | 77.6 | ||
| BMI, kg/m2 | Smoking, % | Education, years | AHI | Hypertension, % | Diabetes mellitus, % | ||||||||
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | OR; 95% CI | Adjusted |
| 35 | 31.8 | NA | NA | NA | NA | 31.3 | 2.2 | NA | NA | NA | NA | 2.90; 0.56, 15.05 | No |
| 29.6 | 28.4 | 34.9 | 34.4 | NA | NA | 9.4 | 2.3 | 33.3 | 45.3 | 6.3 | 3.1 | 0.71; 0.40, 1.24 | No |
| 31.1 | 28.4 | 30.3 | 34.4 | NA | NA | 20.8 | 2.3 | 56.1 | 45.3 | 10.6 | 3.1 | 0.58; 0.28, 1.19 | No |
| 33.9 | 28.4 | 45.7 | 34.4 | NA | NA | 60.4 | 2.3 | 62.3 | 45.3 | 17.6 | 3.1 | 0.77; 0.47, 1.27 | No |
| 25.5 | 24.2 | NA | NA | 17.2 | 16.2 | 8.3 | 2.3 | 29.4 | 24.0 | 7.8 | 8.0 | 1.18; 0.41, 3.37 | No |
| 28.9 | 24.2 | NA | NA | 16.3 | 16.2 | 30.7 | 2.3 | 31.6 | 24.0 | 5.3 | 8.0 | 1.19; 0.32, 4.37 | No |
| 32.5 | 28.9 | 12.0 | 14.5 | 14.2 | 14.7 | 8.7 | 1.4 | 34.8 | 20.5 | NA | NA | 0.81; 0.62, 1.06 | No |
| 36.6 | 28.9 | 11.4 | 14.5 | 14.0 | 14.7 | 29.4 | 1.4 | 51.3 | 20.5 | NA | NA | 1.14; 0.86, 1.50 | No |
| 36.1 | 30.2 | 45.5 | 20.0 | 8.1 | 7.4 | NA | NA | 61.8 | 57.1 | 18.7 | 8.6 | 1.22; 0.64, 2.31 | No |
| 29.58 | 24.71 | NA | NA | NA | NA | NA | NA | NA | 0.0 | NA | 0.0 | 7.12; 3.41, 14.89 | No |
| NA | NA | NA | NA | NA | NA | NA | NA | 0.0 | 0.0 | 0.0 | 0.0 | 3.50; 1.05, 11.66 | No |
| 17 | 16.9 | NA | NA | NA | NA | 8.6 | 0.8 | NA | NA | NA | NA | 4.47; 1.27, 15.75 | No |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1.03; 0.69, 1.53 | No |
| 29.6 | 30.3 | NA | NA | NA | NA | NA | NA | 23.6 | 28.7 | NA | NA | 0.85; 0.56, 1.00 | Yes |
| 31.1 | 30.3 | NA | NA | NA | NA | NA | NA | 35.0 | 28.7 | NA | NA | 0.64; 0.42, 0.98 | Yes |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1.41; 1.06, 1.87 | Yes |
| 30 | 30 | 16.4 | 16.4 | NA | NA | NA | NA | 33.0 | 33.0 | NA | NA | 2.00; 1.20, 3.50 | Yes |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0.77; 0.52, 1.14 | Yes |
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1.00; 0.75, 1.33 | No |
AHI, apnoea–hypopnea index; BMI, body mass index; OR, odds ratio; 95% CI, 95% confidence interval. Pro, prospective; Retro, retrospective; Hosp, hospital; Pop, population; PSG, polysomnography; NPI-D, neuropsychiatric inventory with caregiver distress; NA, not available;
Figure 2.Forest plot of a meta-analysis of the association between obstructive sleep apnoea (OSA) risk and the apolipoprotein gene (APOE) ɛ4 allele.[10–23] The colour version of this figure is available at: http://imr.sagepub.com.
Figure 3.Begg’s and Filled funnel plots for a meta-analysis of the association between obstructive sleep apnoea (OSA) risk and the apolipoprotein gene (APOE) ɛ4 allele.[10–23]
Body mass index and lipid parameters in apolipoprotein gene (APOE) ɛ4-positive and negative individuals.
| Parameter | Studies, |
| WMD | 95% CI | Statistical significance | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| ɛ4+ | ɛ4− | ||||||
| BMI, kg/m2 | 4 | 713 | 2017 | 0.027 | −0.817, 0.871 | NS | |
| TG, mmol/l | 4 | 713 | 2017 | 0.203 | −0.085, 0.491 | NS | |
| TC, mmol/l | 4 | 713 | 2017 | 0.342 | 0.095, 0.590 | ||
| HDLC, mmol/l | 4 | 713 | 2017 | −0.052 | −0.103, −0.002 | ||
| LDLC, mmol/l | 3 | 274 | 681 | 0.197 | −0.097, 0.491 | NS | |
WMD, weighted mean difference; CI, confidence interval; BMI, body mass index; NS, not statistically significant (P ≥ 0.05; random effects model); TG, triglyceride; TC, total cholesterol; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol.
Stratified analyses of the association between obstructive sleep apnoea (OSA) risk and the apolipoprotein gene (APOE) ɛ4 allele.
| Subgroups | Studies, |
| OR | 95% CI | Heterogeneity | |
|---|---|---|---|---|---|---|
| Patients | Controls | |||||
| Study design | ||||||
| Prospective | 10 | 1930 | 6544 | 1.02 | 0.82, 1.28 | |
| Retrospective | 9 | 1268 | 1710 | 1.33 | 0.86, 2.05 | |
| Source of controls | ||||||
| Population-based | 13 | 2498 | 7614 | 1.20 | 0.93,1.55 | |
| Hospital-based | 6 | 700 | 640 | 0.64, 1.38 | ||
| AHI cut off | ||||||
| >5–<15 | 3 | 577 | 1299 | 0.88 | 0.64, 1.02 | |
| ≥15 | 10 | 1825 | 5719 | 0.99 | 0.79, 1.24 | |
| ≥5 | 4 | 467 | 905 | 2.82 | 0.84, 9.45 | |
| Total sample size | ||||||
| <500 | 11 | 1090 | 1063 | 1.45 | 0.91, 2.31 | |
| ≥500 | 8 | 2108 | 7191 | 1.00 | 0.81, 1.22 | |
| Chinese subjects | 2 | 134 | 146 | 5.87 | 3.13, 11.00 | |
OR, odds ratio; CI, confidence interval; AHI, apnoea–hypopnea index.
Figure 4.Meta-regression analysis of the association between hypertension and risk of obstructive sleep apnoea (OSA). The colour version of this figure is available at: http://imr.sagepub.com.